Heart Outcomes Prevention Evaluation (HOPE) Study

Introduction

The study tested the effect of the ACE inhibitor ramipril in 9297 patients at high risk for myocardial infarction (vascular disease or diabetes plus one other cardiovascular risk factor). Ramipril 10 mg QD was tested against placebo for a period of 5 years.

The study found that the ramipril group had lower rates of:

• death from cardiovascular causes (6.1% vs 8.1%)
• MI (10% vs 12%)
• death from any cause (10% vs 12%)
• revascularization procedures (16% vs 18%)
• cardiac arrest (0.8% vs 1.3%)
• heart failure (9.0% vs 11.5%)
• complications due to diabetes (6.4% vs 7.6%)
• new cases of diabetes (34% reduction)

More general terms

• clinical trial

Additional terms

• HOPE & HOPE Too trials